Does evolocumab lower LDL cholesterol in diabetics without atherosclerosis after 48 weeks?

1 min readUpdated June 7, 2026

What the Evidence Shows

We analyzed the available evidence on evolocumab and LDL cholesterol in people with diabetes but no advanced artery disease, and what we’ve found so far suggests it lowers LDL levels after 48 weeks. One assertion shows that in this group, evolocumab reduced LDL from 111 mg/dL to 52 mg/dL when used...

Evidence from Studies

Supporting (0)
No supporting evidence found
Contradicting (0)
No contradicting evidence found
Primary Studies (1)

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

DOI: 10.1001/jama.2026.3277

Update History

Published
June 7, 2026·Last updated June 7, 2026
  • Invalid DateNew topic created from assertion

Sign up to see full analysis